Compare ARCT & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | KRRO |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.1M | 187.9M |
| IPO Year | 2019 | 2019 |
| Metric | ARCT | KRRO |
|---|---|---|
| Price | $5.52 | $11.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $24.11 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 564.0K | 224.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,031,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $5.74 | $5.20 |
| 52 Week High | $24.14 | $55.89 |
| Indicator | ARCT | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 37.08 |
| Support Level | N/A | $10.81 |
| Resistance Level | $7.98 | $14.53 |
| Average True Range (ATR) | 0.36 | 0.97 |
| MACD | -0.10 | -0.33 |
| Stochastic Oscillator | 0.23 | 1.77 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.